YAZ PLUS 3.00 MG — DIN 02387433
DROSPIRENONE : 3.00 MG LEVOMEFOLATE CALCIUM : 0.451 MG LEVOMEFOLATE CALCIUM : 0.451 MG ETHINYL ESTRADIOL : 0.02 MG · BAYER INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is YAZ PLUS?
YAZ PLUS 3.00 MG contains DROSPIRENONE : 3.00 MG LEVOMEFOLATE CALCIUM : 0.451 MG LEVOMEFOLATE CALCIUM : 0.451 MG ETHINYL ESTRADIOL : 0.02 MG. It is listed in the Health Canada Drug Product Database under DIN 02387433, held by BAYER INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 01-Mar-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
How much does Drospirenone And Estrogen cost around the world?
Drospirenone And Estrogen is listed on 6 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Saudi Arabia publishes a public. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 13 | 26 | AUD███.██ |
| South Africa | single exit price | 21 | 21 | ZAR███.██ |
| Bahrain | retail (max) | 5 | 5 | BHD███.██ |
| Saudi Arabia | public | 4 | 4 | SAR███.██ |
| United Arab Emirates | public | 3 | 3 | AED███.██ |
| United Kingdom | hospital | 1 | 1 | GBP███.██ |
60 pack listings across 47 brand entries and 5 price bases, refreshed 08 Sep 2026. Ranges span every Drospirenone And Estrogen pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Drospirenone And Estrogen in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
6 holders have a Canadian DIN containing Drospirenone And Estrogen, across 20 DINs, of which 10 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BAYER INC | 5 | 4 | YASMIN 21, YASMIN 28, YASMIN PLUS, YAZ, YAZ PLUS | Sourceable in Canada |
| APOTEX INC | 3 | 3 | MYA, ZAMINE 21, ZAMINE 28 | Sourceable in Canada |
| GLENMARK PHARMACEUTICALS CANADA INC. | 3 | 3 | DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS USP, DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS USP 21, DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS USP 28 | Sourceable in Canada |
| COBALT PHARMACEUTICALS COMPANY | 3 | 0 | VESTURA, ZARAH 21, ZARAH 28 | No marketed DIN |
| LUPIN LIMITED | 3 | 0 | NIKKI, QISMETTE 21, QISMETTE 28 | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 3 | 0 | DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS, DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS 21, DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS 28 | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 3.00 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Drospirenone And Estrogen |
|---|---|
| ATC code | G03AA12 |
| AHFS class | 68:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02387433 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2387433 |
| Brand name | YAZ PLUS |
| Generic / active ingredient | DROSPIRENONE : 3.00 MG LEVOMEFOLATE CALCIUM : 0.451 MG LEVOMEFOLATE CALCIUM : 0.451 MG ETHINYL ESTRADIOL : 0.02 MG |
| Market authorization holder | BAYER INC |
| Health Canada schedule | Prescription |
| ATC code | G03AA12 |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G03AA |
| Current status | MARKETED |
| Status date | 01-Mar-2013 |
| Original market date | 2013-03-01 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Drospirenone And Estrogen in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by GLENMARK PHARMACEUTICALS CANADA INC., last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
10 of 20 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS USP | 0.02 MG | TABLET | GLENMARK PHARMACEUTICALS CANADA INC. | MARKETED | 02462060 |
| DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS USP 21 | 3 MG | TABLET | GLENMARK PHARMACEUTICALS CANADA INC. | MARKETED | 02421437 |
| DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS USP 28 | 0.03 MG | TABLET | GLENMARK PHARMACEUTICALS CANADA INC. | MARKETED | 02421445 |
| MYA | 3.00 MG | TABLET | APOTEX INC | MARKETED | 02415380 |
| YASMIN 21 | 0.03 MG | TABLET | BAYER INC | MARKETED | 02261723 |
| YASMIN 28 | 0.03 MG | TABLET | BAYER INC | MARKETED | 02261731 |
| YAZ | 3 MG | TABLET | BAYER INC | MARKETED | 02321157 |
| ZAMINE 21 | 3 MG | TABLET | APOTEX INC | MARKETED | 02410788 |
| ZAMINE 28 | 3 MG | TABLET | APOTEX INC | MARKETED | 02410796 |
| DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS | 0.02 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED PRE MARKET | 02425726 |
2 · Same class — other molecules in ATC G03AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Levonorgestrel And Estrogen | ALESSE 21 · ALESSE 28 · ALYSENA 21 · ALYSENA 28 · +22 more | 26 | 18 | Yes |
| Drospirenone And Estrogen | DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS · DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS 21 · DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS 28 · DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS USP · +16 more | 20 | 10 | Yes |
| Desogestrel And Estrogen | APRI 21 · APRI 28 · FREYA 21 · FREYA 28 · +12 more | 16 | 10 | Yes |
| Norethisterone And Estrogen | BREVICON 0.5/35 21 TAB · BREVICON 0.5/35 28 TAB · BREVICON 0.5/35 TABLETS (21-DAY PACK) · BREVICON 0.5/35 TABLETS (28-DAY PACK) · +19 more | 25 | 6 | Yes |
| Norelgestromin And Estrogen | EVRA · EVRA -(6/0.75) | 2 | 1 | Yes |
| Drospirenone And Estetrol | NEXTSTELLIS | 1 | 1 | Yes |
| Norgestimate And Estrogen | CYCLEN TABLETS (21 DAY) · CYCLEN TABLETS (28 DAY) · PREVIFEM (21DAY) · PREVIFEM (28DAY) · +2 more | 6 | 0 | Not in Canada |
| Norgestrel And Estrogen | LO-FEMENAL 21 TABLETS · OVRAL 21 · OVRAL 21 TAB · OVRAL 28 TABLETS · +1 more | 5 | 0 | Not in Canada |
| Etynodiol And Estrogen | DEMULEN 30 (21 DAY PACK) · DEMULEN 30 (28 DAY PACK) · DEMULEN 50 (21 DAY PACK) · DEMULEN 50 (28 DAY PACK) | 4 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC G03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| G03AB | Desogestrel And Estrogen · Dienogest And Estrogen · Levonorgestrel And Estrogen · Norethisterone And Estrogen · Norgestimate And Estrogen · +2 more | 40 | 14 |
| G03AC | Drospirenone · Etonogestrel · Levonorgestrel · Medroxyprogesterone · Norethisterone · +1 more | 13 | 6 |
| G03AD | Levonorgestrel · Ulipristal | 14 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is YAZ PLUS called?
The same molecule, Drospirenone And Estrogen, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Slinda | Latin | Australia, Bahrain, Saudi Arabia |
| Yasmin | Latin | Australia, Bahrain, South Africa |
| Yaz | Latin | Australia, Bahrain |
| Bella | Latin | Australia |
| Brooke | Latin | Australia |
| Brooklynn | Latin | Australia |
| Isabelle | Latin | Australia |
| Lucinda | Latin | Australia |
| Mila | Latin | Australia |
| Rosalee | Latin | Australia |
| Rosie | Latin | Australia |
| YANA | Latin | Australia |
| Yelena | Latin | Australia |
| Angeliq | Latin | South Africa |
| ANGELIQ F-C TABLETS | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.